MNA 279

MNA 279 (X 910279) is an orally active, immunosuppressive malononitrilamide and A 771726 derivative. MNA 279 suppresses IgM and IgG antibody production. MNA 279 prevents the development of systemic lupus erythematosus (SLE) -like disease in mice. MNA 279 prolongs skin xenograft survival in a mouse-to-rat model[1][2].

Product Specifications

CAS Number

[185915-32-6]

Product Name Alternative

X 910279; HMR-279; FK-779

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Drug Derivative

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

N#CC1=CC=C(NC(C(C(C2CC2)=O)C#N)=O)C=C1

Molecular Formula

C14H11N3O2

Molecular Weight

253.26

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Schorlemmer HU, et al. Prevention of the development of murine systemic lupus erythematosus (SLE) -like diseases by the malononitrilamides MNA 279 and MNA 715. Inflamm Res. 1997 Aug;46 Suppl 2:S167-8. |[2]Schorlemmer HU, et al. The new immunosuppressive malononitrilamide MNA 279 prolongs skin xenograft survival in a mouse-to-rat model. Transplant Proc. 1997 Dec;29 (8) :3497-500.